Background: Broadband UV-B phototherapy has been used for many years in the treatment of small plaque parapsoriasis (SPP) and early-stage mycosis fungoides (MF). Our purpose was to investigate the effect on these diseases of narrowband (311-nm) UV-B therapy, which was recently established for the treatment of psoriasis and found to be more effective than broadband UV-B therapy.
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(range, 7.4-36.4 J/cm 2 ) within a mean time of 6 weeks (range, 5-10 weeks). Biopsy specimens taken immediately after the end of phototherapy showed only sparse inflammatory infiltrates but no signs of SPP or MF. Relapses at cutaneous sites occurred in all patients within a mean time of 6 months (range, 2-15 months).
Conclusions: Narrowband UV-B therapy is an effective short-term treatment modality for clearing SPP and earlystage MF. However, the treatment response did not sustain long-term remission. Further studies are necessary to examine how the clinical response to and follow-up after narrowband UV-B therapy compares with that of established phototherapy modalities in these diseases.
Arch Dermatol. 1999; 135:1377 -1380 T REATMENT OF small and large plaque parapsoriasis and mycosis fungoides (MF) for many years has consisted of UV-B 1 as well as psoralen-UV-A (PUVA) 2-6 therapy. Although large plaque parapsoriasis is considered an early form of MF, the relation of small plaque parapsoriasis (SPP) to MF is still a matter of discussion. [7] [8] [9] However, to prevent early-stage MF from progressing, an early aggressive therapy and careful monitoring of the patients may be necessary. 10 Narrowband UV-B was introduced recently for the treatment of psoriasis and found to be more effective than broadband UV-B at clearing psoriatic lesions. 11 Indeed, even when compared with PUVA photochemotherapy, narrowband UV-B was reported to have on average the same efficacy but fewer side effects. 12 Therefore, the purpose of our study was to investigate the effect of narrowband (311-nm) UV-B in patients with SPP and early-stage MF.
RESULTS
All 20 patients completed the study, and 19 (95%) had a complete clinical remission (patients with SPP, 14 of 14; patients with MF, 5 of 6) ( Table 1 In the follow-up period, relapses occurred in all patients within a mean time of 6 months (range, 2-15 months) (Table and Figure 3 ). There was no statistically significant difference in the primary response rate (Fisher exact test, P = .30) or in the response rate on long-term follow-up (log- rank test, P = .73) between patients with SPP and those with early-stage MF (patch stage) ( Figure 3 ). In 7 (37%) of 19 patients who had complete clearance, the skin changes associated with relapse were less widespread and intense, and topical steroids were then effective at producing clearance again. Five patients (patients 1, 2, 12, 13, and 18) were again treated with 311-nm UV-B and again responded with complete clearing (data not shown). 
PATIENTS AND METHODS

PATIENTS
Twenty patients with histologically confirmed SPP or early-stage MF were enrolled in the study, after giving their informed consent. Their demographic and phototherapeutic data are given in Table. Diagnoses were made according to clinical and histopathological findings. 13 Fourteen patients (2 women and 12 men; mean age, 51 years; age range, 39-67 years) had small, oval, red-brown, slightly scaly patches symmetrically distributed on the limbs and trunk; these were all classified clinically and histopathologically as SPP. In these 14 patients, the mean disease duration was 7 years (range, 6 months to 17.5 years). Six patients (3 women and 3 men; mean age, 71.5 years; age range, 57-85 years) showed large red-brown patches (some of which were slightly wrinkled), mostly on the trunk; these were classified clinically and histopathologically as patch-stage MF (stage IA and IB, according to the National Cancer Institute classification 14 ) (Figure 1 ). In these 6 patients, the mean disease duration was 11 years (range, 1.5-25 years). None of the patients had enlarged axillary or inguinal lymph nodes. There were no abnormalities in red or white blood cell counts in any of the patients. The results of all other routine investigations were within normal limits.
LIGHT SOURCE AND TREATMENT
Therapy was given in a UV irradiation cubicle (Waldmann 7001; Waldmann Medizinische Technik, Gevelsberg, Germany) equipped with 40 100-W fluorescent lamps (TL-01; Philips Company, Eindhoven, the Netherlands). The mean light intensity of the UV cubicle was 7.41 mW/ cm 2 as measured by the integrated light-detecting instrument. Therapy was given 3 to 4 times a week until more than 95% clearing of the patient's skin lesions had occurred. The initial treatment dose was 70% of a patient's individual minimal 311-nm UV-B erythema dose. The UV dose was increased weekly by 20% if previous treatments had caused no or slight erythema. The dose was not increased if previous treatments had produced marked erythema. During the study and the follow-up period, only emollients were permitted for topical skin care.
DETERMINATION OF CLINICAL RESPONSE
Clinical response was rated as follows: complete response, more than 95% clearing of skin lesions; partial response, 50% to 95%; and no response, less than 50%. Before and after therapy, 4-mm punch biopsy specimens were taken from each patient at the site of a representative skin lesion for histologic examination. The specimens were processed routinely and stained with hematoxylin-eosin for light microscopic examination.
COMMENT
To our knowledge, this is the first study showing that narrowband UV-B therapy is effective in clearing skin lesions of SPP and early-stage MF. Treatment with 311-nm UV-B cleared the skin lesions in 100% of patients with SPP and all but 1 patient with early-stage MF (Figure 1 ) within a mean time of 6 weeks. However, in the follow-up period, relapses occurred in all patients within a mean time of 6 months. One possible reason why relapse occurred so relatively quickly in all cases of SPP and early-stage MF treated with 311-nm UV-B may have been the lack of maintenance therapy and/or slow tapering schedule after remission.
Compared with broadband UV-B therapy, 311-nm UV-B therapy as applied herein seemed to induce an equal or even higher primary response rate in patients with SPP as well as those with early-stage MF. 1, 15 For instance, Ramsay et al 1 showed in a retrospective nonrandomized study of 37 patients with early (stages IA-IIB) cutaneous T-cell lymphoma (CTCL) that broadband UV-B treatment produced complete clearance in 25 (83%) of 30 patients with stage I CTCL after a median time of 5 months, but produced no response in any patients with stage II CTCL. Among the patients who achieved complete remission, 5 (20%) had a relapse after a median time of 5 months (range, 1-33 months); in 2 of these patients, relapse occurred during UV-B maintenance therapy, which was given to all patients for at least 3 months. Resnik table analysis for the follow-up of patients with small plaque parapsoriasis (SPP) (n = 14) and early-stage mycosis fungoides (MF) (n = 6) treated with 311-nm UV-B therapy. There was no statistically significant difference in the disease-free rate between patients with SPP and MF (log-rank test, P = .73).
